Welcome to our dedicated page for Caribou Biosciences SEC filings (Ticker: CRBU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Caribou Biosciences filings document a clinical-stage CRISPR genome-editing biopharmaceutical company focused on allogeneic CAR-T therapies. Recent 8-K reports furnish quarterly and annual financial results, cash and operating-plan disclosures, business updates, and Regulation FD disclosures covering vispa-cel and CB-011 clinical and FDA-related developments.
Proxy materials describe annual meeting matters, board elections, auditor ratification, and proposed charter governance changes for the Delaware corporation. Other event filings record public-company status matters, including Nasdaq bid-price compliance notices and product-candidate regulatory designations.
Caribou Biosciences, Inc. reported continued operating losses while advancing its two allogeneic CAR-T programs, vispacabtagene regedleucel (vispa-cel) and CB-011, for hematologic malignancies. For the six months ended June 30, 2026, licensing and other revenue was $3.9 million and net loss was $49.4 million, a smaller loss than a year earlier largely due to lower research and development and general and administrative spending.
Cash, cash equivalents, and marketable securities totaled $113.8 million, and management expects this to fund the current operating plan for at least 12 months. Operating cash outflow was $49.8 million in the first half, partially offset by $20.1 million in net proceeds from at-the-market equity sales.
The company reached alignment with the FDA on ANTLER-3, a planned pivotal phase 3 trial of vispa-cel in second-line large B cell lymphoma, and reported updated phase 1 data for both vispa-cel and CB-011 showing high response rates and manageable safety profiles in selected subgroups.
Caribou Biosciences, Inc. reported second quarter 2026 results and updated progress on its allogeneic CAR‑T pipeline. For vispacabtagene regedleucel (vispa‑cel) in second‑line large B cell lymphoma, ANTLER phase 1 data in 27 optimized patients showed an 82% overall response rate, 67% complete response rate, and 17.1‑month median progression‑free survival, with a generally well‑tolerated safety profile. The company plans a pivotal ANTLER‑3 phase 3 trial enrolling about 250 CD19‑naïve 2L LBCL patients.
For CB‑011 in relapsed or refractory multiple myeloma, CaMMouflage phase 1 dose‑escalation data at the 450‑million‑cell dose in 12 BCMA‑naïve patients showed a 92% overall response rate, 83% ≥CR rate, and 91% MRD negativity, with durable responses after a single dose. Caribou is enrolling BCMA‑naïve and BCMA‑exposed patients in dose expansion, with initial expansion data expected in the second half of 2026.
Financially, second‑quarter 2026 licensing and other revenue was $1.5 million versus $2.7 million a year earlier. Research and development expenses fell to $18.9 million from $27.7 million, and general and administrative expenses declined to $7.9 million from $10.4 million. GAAP net loss narrowed to $24.3 million, or $0.24 per share, compared with $54.1 million, or $0.58 per share, which previously included $21.3 million in non‑cash impairment charges. Cash, cash equivalents, and marketable securities totaled $113.8 million as of June 30, 2026, and the company expects this to fund its current operating plan, including CB‑011 dose expansion and ANTLER‑3 start‑up activities, to the end of 2027.
BlackRock, Inc. reported beneficial ownership of common stock of Caribou Biosciences, Inc. as of June 30, 2026. BlackRock and certain of its subsidiaries and affiliates collectively beneficially own 7,176,404 shares of Caribou common stock, representing 7.2% of the outstanding class.
BlackRock has sole voting power over 7,110,251 shares and sole dispositive power over 7,176,404 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client has more than five percent of Caribou’s outstanding common shares.
Caribou Biosciences, Inc. reported results of its June 17, 2026 annual stockholder meeting. Stockholders elected three Class II directors — Andrew Guggenhime, David Johnson, and Nancy Whiting — to serve until the 2029 annual meeting.
They also ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. An amendment to the certificate of incorporation to provide for officer exculpation from certain fiduciary duty claims did not receive sufficient support and was not approved. Stockholders approved a proposal to permit adjournment of the meeting if necessary, although the company chose not to adjourn.
Caribou Biosciences reported updated clinical data for two off-the-shelf CAR-T cell therapies in blood cancers. In the ANTLER phase 1 trial for second-line large B cell lymphoma, the optimized vispa-cel subgroup (27 patients) showed an 82% overall response rate, 67% complete response rate, and 17.1-month median progression-free survival after a single 80 million-cell dose, with a generally manageable safety profile but including two treatment-related deaths. These data support the design of the planned ANTLER-3 pivotal phase 3 trial in about 250 CD19‑naïve second-line patients.
In the CaMMouflage phase 1 trial for relapsed or refractory multiple myeloma, 12 BCMA‑naïve patients treated at the recommended 450 million-cell dose of CB-011 had a 92% overall response rate, 83% complete or stringent complete response rate, 91% minimal residual disease negativity among evaluable patients, and 50% remaining in complete response or better at 15 months, with one CB‑011‑related death reported across all treated patients. Caribou plans to present these results at the EHA 2026 meeting and expects initial dose expansion data for CB‑011 in the second half of 2026.
Caribou Biosciences reported first-quarter 2026 results showing a narrower net loss as it continues to advance its allogeneic CAR-T pipeline. Licensing and other revenue was $2.4 million, while research and development and general and administrative expenses fell to $20.6 million and $8.1 million, respectively.
Net loss improved to $25.1 million from $40.0 million a year earlier, and operating cash use declined to $27.0 million. As of March 31, 2026, the company held $118.6 million in cash, cash equivalents, and marketable securities, which management believes will fund operations for at least 12 months while it prepares a pivotal phase 3 trial for vispa‑cel and expands CB‑011 development.
Caribou Biosciences reported first quarter 2026 results and highlighted key progress in its allogeneic CAR-T programs. Licensing and other third-party revenue was $2.4 million for the three months ended March 31, 2026, essentially unchanged from $2.4 million a year earlier.
Research and development expenses fell to $20.6 million from $35.5 million, and general and administrative expenses declined to $8.1 million from $9.7 million, reflecting prior workforce reductions and pipeline prioritization. Net loss narrowed to $25.1 million, or $0.26 per share, compared with a $40.0 million loss, or $0.43 per share, in 2025.
Caribou ended the quarter with $118.6 million in cash, cash equivalents, and marketable securities and expects this to fund its current operating plan, including CB-011 dose expansion and start-up activities for the planned pivotal vispa-cel trial, into the second half of 2027. The company also reported FDA alignment on the pivotal ANTLER-3 phase 3 design for vispa-cel and RMAT designation for CB-011 based on promising phase 1 data.
Caribou Biosciences, Inc. filed an amendment to its definitive proxy statement to correct a clerical error in the reported shares outstanding and to reconfirm details for its virtual 2026 Annual Meeting. The corrected shares outstanding on the record date are 98,258,898 as of April 20, 2026. The annual meeting is scheduled for June 17, 2026 in a virtual format and includes voting on (1) election of three Class II directors, (2) ratification of Deloitte & Touche LLP as independent auditors, (3) approval of an amendment to permit officer exculpation under Delaware law, and (4) an adjournment proposal to permit further solicitation if needed. The amendment notes that percentages in the beneficial ownership table were updated to reflect the corrected outstanding share count and states there are no other material changes to the originally filed proxy statement.
Caribou Biosciences, Inc. filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, describing its clinical-stage CRISPR chRDNA genome-editing platform and two lead allogeneic CAR-T product candidates: vispa-cel (anti-CD19) and CB-011 (anti-BCMA). The filing summarizes clinical results and development plans, regulatory designations, manufacturing strategy, collaborations, intellectual property, and a workforce reduction announced April 24, 2025, as part of a pipeline prioritization.
The filing reports clinical data cutoffs for vispa-cel and CB-011, ongoing engagement with the FDA on a planned pivotal phase 3 for vispa-cel, a strategic investment and information-rights arrangement with Pfizer, patent and license positions, and key risks including continued operating losses and the need for additional financing.
Caribou Biosciences, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 17, 2026. Investors will elect three Class II directors to serve until the 2029 meeting, ratify Deloitte & Touche LLP as auditor for 2026, and consider an amendment to the certificate of incorporation to add officer exculpation to the fullest extent permitted by Delaware law. Stockholders will also vote on a proposal to adjourn the meeting, if needed, to secure sufficient support for the charter amendment or to reach a quorum. The proxy discloses that 98,682,370 common shares are entitled to vote and provides detailed information on board composition, independence, executive roles, and 2024–2025 executive compensation, including salaries, cash bonuses, and equity awards.